The policy identifies multiple devices and procedures as unproven or not medically necessary for the treatment of obstructive or central sleep apnea when there is insufficient quality evidence of efficacy or when safety concerns have been raised. Examples explicitly listed include positional OSA devices, nasal dilators, intranasal expiratory resistance valves, removable oral appliances for central sleep apnea (CSA), prefabricated (ready‑made) oral appliances, non‑surgical electrical muscular training, mandibular vertical repositioning devices (e.g., Slow Wave), morning repositioning devices, epigenetic and Advanced Lightwire Functional (ALF) appliances, and a set of surgical procedures (including LAUP, lingual suspension, isolated hyoid myotomy, stand‑alone uvulectomy, palatal implants, radiofrequency ablation, TORS, and DOME).
For certain procedures there are specific safety and evidence concerns noted: LAUP has inconsistent efficacy in published series and systematic reviews and has been associated with a high complication rate (reported as ~256 complications per 1,000 procedures in pooled reviews), raising both effectiveness and safety concerns; palatal implants show mixed RCT results with only small‑to‑moderate treatment effects in some studies and are discouraged by some guidance bodies; and removable oral appliances for CSA have no identified relevant evidence supporting their use because CSA is neurogenic rather than primarily an anatomic obstruction.
The policy emphasizes that FDA clearance or approval is informational only and not by itself sufficient to establish coverage; absent convincing evidence of clinical benefit and appropriate indication, devices or procedures may be considered investigational or not medically necessary. Finally, providers should confirm individual member benefit plan terms because member‑specific coverage rules govern and may differ from the standard policy.